Updates on the pathologic diagnosis and classification of mesothelioma

Abstract

Mesothelioma is a rare malignant tumor of the serosal membranes that can be challenging to diagnose, especially on small biopsy specimens. There are updated guidelines on the diagnosis and classification of mesothelioma, which incorporate advancements in understanding mesothelioma biology published in the literature over recent years. This review will discuss marked developments and/or improvements that have been made, including: (1) to the histologic classifications of mesothelioma; (2) the use of such classifications and nuclear grading in prognosis; (3) the indispensability of ancillary studies in the diagnosis of mesothelioma; (4) the application of these pleural based classifications and diagnostic schemes in peritoneal mesothelioma; and (5) the potential for diagnosis of mesothelioma in situ.

Keywords

Mesothelioma / BRCA associated peptide 1 (BAP1) / methylthioadenosine phosphorylase (MTAP) / nuclear grading / mesothelioma in situ

References

[1] Kim J,Labow DM.Malignant peritoneal mesothelioma: a review.Ann Transl Med2017;5:236 PMCID:PMC5497105

[2] Mott FE.Mesothelioma: a review.Ochsner J2012;12:70 PMCID:PMC3307510

[3] Henley SJ,Wu M.Mesothelioma incidence in 50 states and the district of Columbia, United States, 2003-2008.Int J Occup Environ Health2013;19:1-10 PMCID:PMC4406225

[4] Moolgavkar SH,Turim J.Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005.Cancer Causes Control2009;20:935-44

[5] Beasley MB,Dacic S.Pleural mesothelioma classification update.Virchows Arch2021;478:59-72

[6] Gelvez-Zapata SM,Scarci M.What is the survival after surgery for localized malignant pleural mesothelioma?.Interact Cardiovasc Thorac Surg2013;16:533-7 PMCID:PMC3598041

[7] Marchevsky AM,Walts AE.Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel.Mod Pathol2020;33:281-96

[8] Editorial Board WC of T Thoracic tumours: WHO classification of tumours, 5th ed. World Health Organization: Geneva, Switzerland, 2021.

[9] Travis WD,Burke A,Nicholson AG. WHO classification of tumours of the lung, pleura, thymus and heart, 5th ed. International Agency for Research on Cancer: Lyon, France, 2015.

[10] Nicholson AG,Nowak AK.EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach.J Thorac Oncol2020;15:29-49

[11] Husain AN,Ordóñez NG.Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the international mesothelioma interest group.Arch Pathol Lab Med2018;142:89-108

[12] Sauter JL,Galateau-Salle F.The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification.J Thorac Oncol2022;17:608-22

[13] Rosen LE,Ananthanarayanan V.Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study.Mod Pathol2018;31:598-606

[14] Kadota K,Colovos C.A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma.Mod Pathol2012;25:260-71 PMCID:PMC4080411

[15] Pelosi G,Righi L.Pathologic grading of malignant pleural mesothelioma: an evidence-based proposal.J Thorac Oncol2018;13:1750-61

[16] Klebe S,Mahar A.Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases.Mod Pathol2010;23:470-9

[17] Mansfield AS,Peikert T.Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials.Lung Cancer2014;86:133-6 PMCID:PMC4254081

[18] Galateau Salle F,Tirode F.Comprehensive molecular and pathologic evaluation of transitional mesothelioma assisted by deep learning approach: a multi-institutional study of the international mesothelioma panel from the MESOPATH reference center.J Thorac Oncol2020;15:1037-53 PMCID:PMC8864581

[19] Galateau Salle F,Nicholson AG.New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center.J Thorac Oncol2018;13:1189-203 PMCID:PMC7558835

[20] Schulte JJ,Attanoos R.Comparison of nuclear grade, necrosis, and histologic subtype between biopsy and resection in pleural malignant mesothelioma: an international multi-institutional analysis.Am J Clin Pathol2021;156:989-99

[21] Chirieac LR,Foo WC.Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma.Cancer2019;125:4164-71 PMCID:PMC7341068

[22] Vigneswaran WT,Ananthanarayanan V.Amount of epithelioid differentiation is a predictor of survival in malignant pleural mesothelioma.Ann Thorac Surg2017;103:962-6

[23] Zhang YZ,Molyneaux PL.Presence of pleomorphic features but not growth patterns improves prognostic stratification of epithelioid malignant pleural mesothelioma by 2-tier nuclear grade.Histopathology2020;77:423-36

[24] Zhang YZ,Molyneaux PL.Utility of nuclear grading system in epithelioid malignant pleural mesothelioma in biopsy-heavy setting: an external validation study of 563 cases.Am J Surg Pathol2020;44:347-56

[25] Fuchs TL,Aksoy Y.A critical assessment of current grading schemes for diffuse pleural mesothelioma with a proposal for a novel mesothelioma weighted grading scheme (MWGS).Am J Surg Pathol2022;46:774-85

[26] Marchevsky AM,Hiroshima K.The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.Hum Pathol2017;67:160-8

[27] Le Stang N,Blaizot G.Differential diagnosis of epithelioid malignant mesothelioma with lung and breast pleural metastasis: a systematic review compared with a standardized panel of antibodies-a new proposal that may influence pathologic practice.Arch Pathol Lab Med2020;144:446-56

[28] Chapel DB,Husain AN.Application of immunohistochemistry in diagnosis and management of malignant mesothelioma.Transl Lung Cancer Res2020;9:S3-S27 PMCID:PMC7082260

[29] Ordóñez NG.The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma.Am J Surg Pathol2003;27:1031-51

[30] Ordóñez NG.Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update.Hum Pathol2013;44:1-19

[31] Patel A,Siddiqui MT.Utility of claudin-4 versus BerEP4 and B72.3 in pleural fluids with metastatic lung adenocarcinoma.J Am Soc Cytopathol2020;9:146-51

[32] Vojtek M,Papadimos DJ.Claudin-4 immunohistochemistry is a useful pan-carcinoma marker for serous effusion specimens.Cytopathology2019;30:614-9

[33] Naso JR.Claudin-4 shows superior specificity for mesothelioma vs non-small-cell lung carcinoma compared with MOC-31 and Ber-EP4.Hum Pathol2020;100:10-4

[34] McGregor SM,Hyjek E,Husain AN.BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.Hum Pathol2015;46:1670-8

[35] Hakim SA.Diagnostic utility of BAP1, EZH2 and survivin in differentiating pleural epithelioid mesothelioma and reactive mesothelial hyperplasia: immunohistochemical study.Pathol Oncol Res2021;27:600073 PMCID:PMC8262140

[36] Chapel DB,Barlow J,Sholl LM.Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma.Mod Pathol2022;

[37] Dagogo-Jack I,Lennerz JK.Molecular characterization of mesothelioma: impact of histologic type and site of origin on molecular landscape.JCO Precis Oncol2022;6:e2100422

[38] Hung YP,Torre M,Bueno R.Molecular characterization of diffuse malignant peritoneal mesothelioma.Mod Pathol2020;33:2269-79

[39] Marshall K,Jones J.Homozygous deletion of CDKN2A in malignant mesothelioma: diagnostic utility, patient characteristics and survival in a UK mesothelioma centre.Lung Cancer2020;150:195-200

[40] Oyama Y,Matsumoto S,Tsujimura T.Short 57 kb.CDKN2A22:813 PMCID:PMC8503810

[41] Nabeshima K,Kinoshita Y,Sa-Ngiamwibool P.Update of pathological diagnosis of pleural mesothelioma using genomic-based morphological techniques, for both histological and cytological investigations.Pathol Int2022;72:389-401

[42] Chapel DB,Hornick JL.Correlation of methylthioadenosine phosphorylase (MTAP) protein expression with MTAP and CDKN2A copy number in malignant pleural mesothelioma.Histopathology2021;78:1032-42

[43] Illei PB,Zakowski MF.Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.Clin Cancer Res2003;9:2108-13

[44] Brcic L,Gallob F.A combination of MTAP and p16 immunohistochemistry can substitute for CDKN2A fluorescence In situ hybridization in diagnosis and prognosis of pleural mesotheliomas.Arch Pathol Lab Med2022;

[45] Hwang HC,Rodriguez S.Utility of BAP1 immunohistochemistry and p16 (CDKN2A) fish in the diagnosis of malignant mesothelioma in effusion cytology specimens.Am J Surg Pathol2016;40:120-6

[46] Berg KB,Miller C,Churg A.Utility of methylthioadenosine phosphorylase compared with BAP1 immunohistochemistry, and CDKN2A and NF2 fluorescence in situ hybridization in separating reactive mesothelial proliferations from epithelioid malignant mesotheliomas.Arch Pathol Lab Med2018;142:1549-53

[47] Kinoshita Y,Hamasaki M.A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.Cancer Cytopathol2018;126:54-63

[48] Naso JR,Senz J,Churg A.Significance of p53 immunostaining in mesothelial proliferations and correlation with TP53 mutation status.Mod Pathol2022;35:77-81

[49] Terra S,Yi ES,Boland JM.Loss of methylthioadenosine phosphorylase by immunohistochemistry is common in pulmonary sarcomatoid carcinoma and sarcomatoid mesothelioma.Am J Clin Pathol2022;157:33-9

[50] Andrici J,Sioson L.Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology.Mod Pathol2015;28:1360-8 PMCID:PMC4761613

[51] Sheffield BS,Lee AF.BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations.Am J Surg Pathol2015;39:977-82

[52] Soeberg MJ,Currow DC,van Zandwijk N.Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972-2009.Aust N Z J Public Health2016;40:255-62

[53] Pavlisko EN,Green C,Roggli VL.Malignant diffuse mesothelioma in women: a study of 354 cases.Am J Surg Pathol2020;44:293-304

[54] Thomas A,Yu T,Prasad V.Distinctive clinical characteristics of malignant mesothelioma in young patients.Oncotarget2015;6:16766-73 PMCID:PMC4599306

[55] Antman K,Ryan L.Malignant mesothelioma: prognostic variables in a registry of 180 patients, the dana-farber cancer institute and brigham and women’s hospital experience over two decades, 1965-1985.J Clin Oncol1988;6:147-53.

[56] Le Stang N,Glehen O.Incidence and survival of peritoneal malignant mesothelioma between 1989 and 2015: A population-based study.Cancer Epidemiol2019;60:106-11

[57] Chapel DB,Absenger G.Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases.Mod Pathol2021;34:380-95

[58] Helm JH,Glenn JA.Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis.Ann Surg Oncol2015;22:1686-93

[59] Pavlisko EN.Sarcomatoid peritoneal mesothelioma: clinicopathologic correlation of 13 cases.Am J Surg Pathol2015;39:1568-75

[60] Malpica A,Marques-Piubelli ML.Malignant mesothelioma of the peritoneum in women: a clinicopathologic study of 164 cases.Am J Surg Pathol2021;45:45-58

[61] Whitaker D,Shilkin KB.The concept of mesothelioma in situ: Implications for diagnosis and histogenesis.Semin Diagn Pathol1992;9:151-61

[62] Dacic S,Lyons MA,Galateau-Salle F.Whole exome sequencing reveals BAP1 somatic abnormalities in mesothelioma in situ.Lung Cancer2020;149:1-4

[63] Churg A,Tan L.Malignant mesothelioma in situ.Histopathology2018;72:1033-8

[64] Fels Elliott DR,As-Sanie S.Progression of peritoneal mesothelioma in situ to invasive mesothelioma arising in the setting of endometriosis with germline BAP1 mutation: a case report.Int J Gynecol Pathol2022;41:535-40

[65] Churg A,Galateau-Salle F,de Perrot M.Malignant mesothelioma in situ: clinical and pathologic implications.J Thorac Oncol2020;15:899-901

[66] Churg A,Roden AC.Malignant mesothelioma in situ: morphologic features and clinical outcome.Mod Pathol2020;33:297-302

[67] Klebe S,Dobra K.The concept of mesothelioma in situ, with consideration of its potential impact on cytology diagnosis.Pathology2021;53:446-53

[68] Pulford E,Klebe S.Malignant mesothelioma in situ: diagnostic and clinical considerations.Pathology2020;52:635-42